PROCRIT® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.
PROCRIT® is not indicated for use:
In anemic patients with cancer with non-myeloid malignancies receiving myelosuppressive chemotherapy
Change in mean Hb values by week on study2
Proportion of patients transfused, Week 5 through Week 16 or end of study
WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
Expand the Important Safety Information at the bottom of the page to see the complete Boxed Warnings.
The adverse reactions with a reported incidence of ≥5% in PROCRIT®-treated patients that occurred at a higher frequency than in placebo-treated patients are shown in the table below:
Adverse reactions in patients with cancer1
|ADVERSE REACTION||PROCRIT®-treated patients (n=168)||Placebo-treated patients (n=165)|